fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

CHMP recommends once-weekly Sogroya to treat growth hormone deficiency – Novo Nordisk

Written by | 8 Feb 2021 | Osteoporosis

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of once-weekly Sogroya (somapacitan), recommending marketing authorisation for the treatment of adults with growth hormone deficiency (AGHD).

The CHMP recommends once-weekly Sogroya (somapacitan) to be indicated for the replacement of endogenous growth hormone in adults with AGHD. Sogroya (somapacitan) is a new long-acting human growth hormone therapy that is taken once a week by injection under the skin. This recommendation is based on the results from REAL 1, a clinical trial programme investigating the efficacy and safety of Sogroya (somapacitan) in adults with growth hormone deficiency.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.